10 April 2026

Understanding EZH2 activities in leukemia, a potential therapeutic strategy

Our research is funded by INCA and the Japanese company ASPIRE as part of a Franco-Japanese collaborative program aimed at improving our understanding of the mechanisms underlying the dysregulation of the EZH2 enzyme in leukemia. Our goal is to shed light on the regulatory mechanisms of EZH2’s oncogenic activity, which could serve as a therapeutic target.
24 September 2025
Couverture article têtes chercheuses Titoff Marseille - CRCM

Titoff and the CRCM researchers

Anne-Sophie Chrétien, Frédéric Bard and Brice Chanez - all three recipients of specific "Pancreatic Cancer" funding from the ARC Foundation -.